Image credit: Canva
CCR researchers are studying NEO-201, a monoclonal antibody, in combination with pembrolizumab to see if it is effective against solid tumors, which are abnormal masses of tissue. A clinical trial led by Kevin C. Conlon, M.D., Associate Research Physician in the Women’s Malignancies Branch, is researching immunotherapy for solid tumors, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), cervical and uterine cancers.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for medical care received at the Clinical Center.
For more information, please contact Ann McCoy, R.N., at (240) 760-6021 or ann.mccoy@nih.gov.
Clinicaltrials.gov identifier: NCT03476681
NCI Protocol ID: 18-C-0147
Official Title: Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
